Peptides and supported peptides for treating skin diseases
The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold proteins is BBI.
1. A composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO: 18, and wherein said peptide binds to a vascular endothelial growth factor.
2. The composition of claim 1 , wherein said SEQ ID NO:18 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-4 and 7.
3. The composition of claim 1 , wherein said scaffold comprises the amino acid sequence set forth in SEQ ID NO:25, wherein said trypsin and chymotrypsin loops are represented by SEQ ID NOs: 20 and 21, respectively.
4. A cosmetic or pharmaceutical composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide of SEQ ID NO:18; and wherein said peptide binds to a vascular endothelial growth factor.
5. The composition of claim 4 , wherein said composition is capable of modulating angiogenesis.
6. The composition of claim 4 , wherein said scaffold comprises the amino acid sequence set forth in SEQ ID NO:25, wherein said trypsin and chymotrypsin loops are respresented by SEQ ID NOs: 20 and 21, respectively.
7. A method for modulating angiogenesis comprising:
i) providing a composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO:18, and wherein said peptide binds to a vascular endothelial growth factor;
ii) providing a subject to be treated, wherein the subject has an angiogenic skin disorder; and
iii) topically applying said composition to said subject in an area in which angiogenesis modulation is desired.
8. The method of claim 1 , wherein said scaffold comprises the amino acid sequence set forth in SEQ ID NO:25, wherein said trypsin and chymotrypsin loops are represented by SEQ ID NOs: 20 and 21.
9. The method of claim 7 , wherein said SEQ ID NO:18 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-4, and 7.
10. A method for decreasing the activity of a vascular endothelial growth factor comprising the steps of:
i) providing a subject, wherein the subject has an angiogenic skin disorder; and
ii) topically administering in an area in which vascular endothelial growth factor inhibition is desired a composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO:18, and wherein said peptide binds to a vascular endothelial growth factor.